By Dr Louise Emmett

Conference Abstracts

Hotta M; Gafita A; Murthy V; Benz MR; Sonni I; Burger IA; Eiber M; Emmett L; Farolfi A; Fendler WP; Weber MM; Hofman MS; Hope TA; Kratochwil C; Czernin J; Calais J, 2023, 'PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [¹⁷⁷Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study', in Journal of Nuclear Medicine, Vol. 64, pp. 1024 - 1029, http://dx.doi.org/10.2967/jnumed.122.265242

Kwok M; McGeorge S; Jiang A; Emmett L; Pattison D; Thomas P; Yaxley J; Roberts M, 2022, 'Dual tracer PET using 68-Ga PSMA and 18-F FDG for staging prostate cancer: A systematic review', in BJU INTERNATIONAL, WILEY, AUSTRALIA, Gold Coast, Vol. 129, pp. 143 - 143, presented at Annual Scientific Meeting of the Urological-Society-of-Australia-and-New Zealand, AUSTRALIA, Gold Coast, 25 June 2022 - 28 June 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000808481200232&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Ptasznik G; Moon D; Emmett L; Papa N; Kelly B; Roberts M; Hofman M; Thompson J; Murphy D; Stricker P, 2022, 'Is a biopsy necessary before offering a radical prostatectomy in all men? An analysis of the PI-RADS 4 & 5 lesions from the PRIMARY trial', in BJU INTERNATIONAL, WILEY, AUSTRALIA, Gold Coast, Vol. 129, pp. 160 - 161, presented at Annual Scientific Meeting of the Urological-Society-of-Australia-and-New Zealand, AUSTRALIA, Gold Coast, 25 June 2022 - 28 June 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000808481200262&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Sandhu S; Joshua AM; Emmett L; Spain LA; Horvath L; Crumbaker M; Anton A; Wallace R; Pasam A; Bressel M; Cassidy E; Banks P; Dhiantravan N; Akhurst TJ; Kumar AR; Alipour R; Scalzo M; Williams S; Hicks R; Hofman MS, 2022, 'PRINCE: Phase I trial of Lu-177-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680301433&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Wong K; Sheehan-Dare G; Nguyen A; Ho B; Liu V; Lee J; Brown LJ; Dear RF-G; Chan L; Pathmanandavel S; Sharma S; Malaroda A; Smith I; Lim E; Emmett L, 2022, '⁶⁴Cu-SAR-Bombesin PET-CT imaging in the staging of ER+/PR+/HER2- metastatic breast cancer: Safety, dosimetry, and feasibility in a phase I trial.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 3092 - 3092, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.3092

Hamid A; Hofman MS; Bressel M; Emmett L; Joshua AM; Spain LA; Horvath L; Crumbaker M; Pasam A; Callahan J; Tubbs A; Fernandez L; Wenstrup RJ; Kong G; Lewin JH; Tran B; Azad A; Schonhoft JD; Hicks RJ; Sandhu S, 2022, 'Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of ¹⁷⁷Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 5027 - 5027, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5027

Hamid A; Hofman MS; Bressel M; Emmett L; Joshua AM; Spain LA; Horvath L; Crumbaker M; Pasam A; Callahan J; Tubbs A; Fernandez L; Wenstrup RJ; Kong G; Lewin JH; Tran B; Azad A; Schonhoft JD; Hicks RJ; Sandhu S, 2022, 'Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of Lu-177-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680301444&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Wong K; Sheehan-Dare G; Nguyen A; Ho B; Liu V; Lee J; Brown LJ; Dear RF-G; Chan L; Pathmanandavel S; Sharma S; Malaroda A; Smith I; Lim E; Emmett L, 2022, 'Cu-64-SAR-Bombesin PET-CT imaging in the staging of ER+/PR+/HER2-metastatic breast cancer: Safety, dosimetry, and feasibility in a phase I trial.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680300985&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Menzies AM; Saw RPM; Lo SN; Gonzalez M; Ch'ng S; Nieweg OE; Shannon KF; Ferguson PM; Lee JHJ; Rizos H; Rawson RV; Stretch J; Thompson JF; Emmett L; Kapoor R; Spillane AJ; Scolyer RA; Long GV, 2022, 'Neoadjuvant dabrafenib and trametinib (D+T) for stage III melanoma: Long-term results from the NeoCombi trial.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 9580 - 9580, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.9580

Sandhu S; Joshua AM; Emmett L; Spain LA; Horvath L; Crumbaker M; Anton A; Wallace R; Pasam A; Bressel M; Cassidy E; Banks P; Dhiantravan N; Akhurst TJ; Ravi Kumar A; Alipour R; Scalzo M; Williams S; Hicks R; Hofman MS, 2022, 'PRINCE: Phase I trial of ¹⁷⁷Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 5017 - 5017, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5017

Hotta M; Gafita A; Murthy V; Benz MR; Sonni I; Burger I; Eiber M; Emmett L; Farolfi A; Fendler WP; Hofman MS; Hope TA; Kratochwil C; Czernin J; Calais J, 2022, 'PSMA PET tumor-to-salivary glands ratio (PSG score) to predict response to Lu-177 PSMA radioligand therapy: An international multicenter retrospective study.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 5043 - 5043, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5043

Hofman MS; Emmett L; Sandhu S; Iravani A; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Francis RJ; Gedye C; Rutherford NK; Zhang AY; McJannett MM; Stockler MR; Williams S; Martin AJ; Davis ID, 2022, 'TheraP: ¹⁷⁷Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel—Overall survival after median follow-up of 3 years (ANZUP 1603).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 5000 - 5000, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5000

Hofman MS; Emmett L; Sandhu S; Iravani A; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Francis RJ; Gedye C; Rutherford NK; Zhang AY; McJannett MM; Stockler MR; Williams S; Martin AJ; Davis ID, 2022, 'TheraP: Lu-177-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-Overall survival after median follow-up of 3 years (ANZUP 1603).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680301419&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Schmidt-Hegemann N-S; Strouthos J; Farolfi A; Trapp C; Peeken J; Vogel MME; Vrachimis A; Belka C; Grosu A-L; Ceci F; Kroeze S; Guckenberger M; Henkenberens C; Emmett L; Zamboglou C; Wiegel T, 2022, 'Influence of PSMA PET-positive local recurrences on biochemical recurrence free survival after salvage radiotherapy in patients with recurrent or persistent prostate cancer-a multicenter retrospective study', in STRAHLENTHERAPIE UND ONKOLOGIE, SPRINGER HEIDELBERG, GERMANY, Stuttgart, Vol. 198, pp. S39 - S39, presented at 28th Congress of Deutsche-Gesellschaft-fur-Radioonkologie-e-V (DERGO), GERMANY, Stuttgart, 26 May 2022 - 28 May 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000791788000073&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Eslick E; Counter W; Sharma S; Ayers M; Wong K; Nguyen A; Ho S; Pathmanandavel S; Hickey A; Emmett L, 2022, 'PSMA Screening phenotype allows personalisation of radiation safety recommendations.', in INTERNAL MEDICINE JOURNAL, WILEY, Vol. 52, pp. 29 - 30, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000794958100059&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Emmett L; Subramaniam S; Martin AJ; Zhang AY; Yip S; Crumbaker M; Rana N; Francis RJ; Hofman MS; Joshua AM; Sandhu SK; Azad A; Gedye C; Weickhardt AJ; Goh JC; Ng S; Voskoboynik M; McJannett MM; Stockler MR; Davis ID, 2022, 'ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.TPS205

Buteau JP; Martin AJ; Emmett L; Iravani A; Sandhu SK; Joshua AM; Zhang AY; Francis RJ; Scott AM; Azad A; McJannett MM; Stockler MR; Williams S; Davis ID; Hofman MS, 2022, 'PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of Lu-177-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.010

Pathmanandavel S; Crumbaker M; Yam AO; Nguyen A; Niman R; Wilson P; Sharma S; Ayers M; Eu P; Stockler MR; Martin AJ; Joshua AM; Emmett L, 2022, 'Quantifying molecular imaging patterns of treatment response or progression using a novel traffic light workflow within a prospective phase I/II trial of 1(77)LuPSMA-617 and NOX66 (LuPIN).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.166

Hotta M; Gafita A; Murthy V; Benz MR; Sonni I; Burger I; Eiber M; Emmett L; Farolfi A; Fendler WP; Hofman MS; Hope TA; Kratochwil C; Czernin J; Calais J, 2022, 'Predicting the outcome of mCPRC patients after Lu-177 PSMA therapy using semi-quantitative and visual criteria in baseline PSMA PET: An international multicenter retrospective study.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at ASCO Genitourinary Cancers Symposium, ELECTR NETWORK, 17 February 2022 - 19 February 2022, http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.032

Meijer D; Vis AN; Roberts MJ; Siriwardana AR; Morton A; Yaxley JW; Samaratunga H; Emmett L; Van de Ven PM; Heijmans MW; Van der Poel HG; Donswijk ML; Boellaard TN; Schoots IG; Oprea-Lager DE; Coughlin GD; Van Leeuwen PJ, 2022, 'Development of a novel nomogram to identify candidates for extended pelvic lymph-node dissection in prostate cancer using MRI and PSMA pet', in EUROPEAN UROLOGY, ELSEVIER, Vol. 81, pp. S981 - S982, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000812320401053&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Doan PN; Counter W; Sheehan-Dare G; Papa N; Ho B; Lee J; Liu V; Thompson J; Agrawal S; Roberts M; Algharzo O; Buteau J; Hofman M; Moon D; Murphy D; Stricker P; Emmett L, 2022, 'Diagnostic accuracy, concordance and certainty with 68Ga-PSMA-11 PET/MRI fusion compared to mpMRI and 68Ga-PSMA-11 PET/CT alone for prostate cancer diagnosis: A PRIMARY trial sub-study', in EUROPEAN UROLOGY, ELSEVIER, Vol. 81, pp. S1103 - S1104, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000812320401137&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Dimitriou F; Lo S; Tan AC; Emmett L; Kapoor R; Carlino M; Long GV; Menzies AM, 2021, 'FDG-PET to predict long-term outcome from anti-PD1 (PD1) therapy in metastatic melanoma', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 32, pp. S880 - S880, presented at Congress of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 16 September 2021 - 21 September 2021, http://dx.doi.org/10.1016/j.annonc.2021.08.1439

Sandhu SK; Joshua AM; Emmett L; Spain L; Horvath LG; Crumbaker M; Anton A; Wallace R; Pasam A; Bressel M; Cassidy E; Banks P; Kumar AR; Alipour R; Akhurst T; Kong G; Davis ID; Williams S; Hicks R; Hofman M, 2021, 'PRINCE: Interim analysis of the phase Ib study of Lu-177-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 32, pp. S626 - S627, presented at Congress of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 16 September 2021 - 21 September 2021, http://dx.doi.org/10.1016/j.annonc.2021.08.1090

Sheehan-Dare G; Lim E; Koo CM; Chan L; Lau B; Dear R; Ho B; Sharma S; Hickey A; Malaroda A; Smith I; Nguyen A; Parker M; Emmett L, 2021, 'Preliminary assessment of the diagnostic value of Cu-64-SAR-Bombesin PET-CT imaging for staging of ER+/PR+HER2-metastatic breast cancer disease: comparison with conventional imaging', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, Vol. 62, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000713713600278&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Hofman MS; Emmett L; Sandhu SK; Iravani A; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Ng S; Francis RJ; Gedye C; Rutherford NK; Zhang AY; McJannett MM; Stockler MR; Violet JA; Williams S; Martin AJ; Davis ID, 2021, '177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel: Updated results including progression-free survival (PFS) and patient-reported outcomes (PROs) (TheraP ANZUP 1603).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.6

Emmett L; Subramaniam S; Zhang AY; Martin AJ; Yip S; Crumbaker M; Rana N; Ford K; Langford A; Francis RJ; Hofman MS; Joshua AM; Sandhu SK; Azad A; Gedye C; McJannett MM; Stockler MR; Davis ID, 2021, 'ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.TPS177

Pathmanandavel S; Crumbaker M; Yam AOW; Rofe C; Ho B; Chan WL; Sharma S; Hickey AJ; Kongrak K; Ratnayake L; Kwan EM; Azad A; Eu P; Nguyen A; Joshua AM; Emmett L, 2021, 'Final results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination 177Lu PSMA 617 and NOX66 in men with end-stage metastatic castration-resistant prostate cancer (LuPIN trial)', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.103

Azad A; Dhiantravan N; Emmett L; Joshua AM; Vela I; Pattison DA; Francis RJ; Williams S; Sandhu SK; Davis ID; Neha N; Bressel M; Murphy DG; Hofman MS, 2021, 'UpFrontPSMA: A randomized phase II study of sequential 177Lu-PSMA617 and docetaxel versus docetaxel in metastatic hormone-naive prostate cancer (mHNPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.TPS180

Roberts M; Tariq A; Morton A; Donato P; Kyle S; Pattison D; Thomas P; Geoff C; Esler R; Dunglison N; Gardiner R; Doi S; Emmett L; Yaxley J, 2020, 'Improved prostate cancer detection and prediction of outcomes using 68Ga PSMA PET/CT: towards non-invasive precision medicine.', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 16, pp. 42 - 43, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000594482700023&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Gondoputro W; Amin A; Blazevski A; Scheltema M; Van Leeuwen P; Van Leeuwen F; Thompson J; Emmett L; Stricker P, 2020, '99m-technetium-labelled PSMA radioguided surgery for the intraoperative detection of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for prostate cancer: preliminary cases from the DETECT trial', in INTERNATIONAL JOURNAL OF UROLOGY, WILEY, Vol. 27, pp. 115 - 115, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000585265700282&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Amin A; Ende J; Stricker P; Emmett L, 2020, 'Pilot trial comparing the performance of 68Ga-PSMA-11 PET/CT to 18F-PSMA-1007 PET/CT in the detection of prostate cancer recurrence in men with rising PSA following radical prostatectomy', in INTERNATIONAL JOURNAL OF UROLOGY, WILEY, Vol. 27, pp. 112 - 112, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000585265700272&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Amin A; Blazevski A; Thompson J; Van Leeuwen P; Emmett L; Stricker P, 2020, 'Early Cases from the DETECT trial: Radioguided Surgery with Technetium99 m-labelled PSMA to aid Intraoperative Lymph Node Metastases Detection for Patients Undergoing Radical Prostatectomy and ePLND for Prostate Cancer', in BJU INTERNATIONAL, WILEY, AUSTRALIA, Sydney, Vol. 125, pp. 86 - 87, presented at 73rd Annual Scientific Meeting of the Urological-Society-of-Australia-and-New Zealand, AUSTRALIA, Sydney, 07 March 2020 - 10 March 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000518206100169&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Ardolino L; Tang R; Pathmanandavel S; Crumbaker M; Joshua A; Emmett L, 2019, 'Lu-177-PSMA-617 as monotherapy or in combination with NOX66 for the treatment of men with late-stage metastatic castrate resistant prostate cancer (mCRPC): An exploratory analysis', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 15, pp. 115 - 115, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000493438400147&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Liu W; Fakir H; Randhawa G; Kassam Z; Chung HT; Chung P; Ward A; Zukotynski K; Emmett L; Bauman G, 2019, 'DRIVE: DEFINING RADIORECURRENT INTRAPROSTATIC TARGET VOLUMES', in RADIOTHERAPY AND ONCOLOGY, ELSEVIER IRELAND LTD, CANADA, Halifax, Vol. 139, pp. S4 - S4, presented at Annual Scientific Meeting of the Canadian-Association-for-Radiation-Oncology (CARO), CANADA, Halifax, 02 October 2019 - 05 October 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000493893300003&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Long GV; Atkinson VG; Lo S; Sandhu SK; Brown M; Gonzalez M; Guminski A; Scolyer RA; Emmett L; Menzies AM; McArthur GA, 2019, 'Long-term outcomes from the randomized phase II study of nivolumab (nivo) or nivo plus ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets): Anti-PD1 brain collaboration (ABC)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Barcelona, Vol. 30, pp. 534 - 534, presented at 44th Congress of the European-Society-for-Medical-Oncology (ESMO), SPAIN, Barcelona, 27 September 2019 - 01 October 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000491295503357&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Liu W; Fakir H; Randhawa G; Kassam Z; Chung HT; Chung P; Ward A; Zukotynski K; Emmett L; Bauman GS, 2019, 'DRIVE: Defining Radiorecurrent Intraprostatic Target Volumes', in INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, ELSEVIER SCIENCE INC, IL, Chicago, Vol. 105, pp. E291 - E291, presented at 61st Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO), IL, Chicago, 15 September 2019 - 18 September 2019, http://dx.doi.org/10.1016/j.ijrobp.2019.06.1834

Amin A; Stricker P; Scheltema M; Blazevski A; Chang J; van Leeuwen P; Quoc N; Ho B; Delprado W; Lee J; Cusick T; Spriensma A; Siriwardena A; O'Neill G; Yuen C; Kooner R; Hruby G; Thompson J; Emmett L, 2019, 'Diagnostic Accuracy of 68GA-PSMA PET and MPMRI to Detect Intra-Prostatic Clinically Significant Prostate Cancer Using Whole-Mount Pathology. Impact of the Addition of 68GA-PSMA PET to MPMRI?', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 15, pp. 42 - 42, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000476915200018&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Emmett L; Crumbaker M; Nguyen A; Ho B; Yin C; Isheish N; Azad A; Violet J; Sharma S; Joshua A, 2019, 'Interim results of a Phase I/II prospective dose escalation trial evaluating safety and efficacy of combination Lu-177 PSMA 617 and NOX66 in men with mCRPC post androgen signalling inhibition and 2 lines of taxane chemotherapy (LuPIN trial)', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, CA, Anaheim, Vol. 60, presented at Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI), CA, Anaheim, 22 June 2019 - 25 June 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000473116800464&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Metser U; Chua S; Ho B; Punwani S; Johnston E; Pouliot F; Tau N; Hawsawy A; Anconina R; Bauman G; Hicks R; Weickhardt A; Davis I; Pond G; Scott A; Emmett L, 2019, 'The contribution of multiparametric pelvic and whole body MR to the interpretation of F-18-fluoromethylcholine(FCH) or Ga-68-HBED-CC PSMA-11 (PSMA) PET/CT in the detection of pelvic recurrence or distant metastases in patients with biochemical failure following radical prostatectomy.', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, CA, Anaheim, Vol. 60, presented at Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI), CA, Anaheim, 22 June 2019 - 25 June 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000473116800591&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Emmett L; Chalasani V; Kneebone A; Hruby G; Joshua AM, 2019, 'Rapid modulation of PSMA expression by ADT: Serial PSMA PET in men commencing androgen blockade.', in RADIOTHERAPY AND ONCOLOGY, ELSEVIER IRELAND LTD, ITALY, Milan, Vol. 133, pp. S445 - S446, presented at 38th Annual Meeting of the European-Society-for-Radiotherapy-and-Oncology (ESTRO), ITALY, Milan, 26 April 2019 - 30 April 2019, http://dx.doi.org/10.1016/S0167-8140(19)31267-8

Hofman M; Emmett L; Violet JA; Lawrence NJ; Williams S; Stockler MR; Francis RJ; Iravani A; Zhang AY; Martin AJ; Azad A; Yip S; Langford A; McJannett MM; Davis ID, 2019, 'TheraP: A randomized phase II trial of [Lu-177]-PSMA-617 theranostic versus cabazitaxel in progressive metastatic castration-resistant prostate cancer', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, Vol. 37, presented at ASCO-SITC Clinical Immuno-Oncology Symposium, CA, San Francisco, 28 February 2019 - 02 March 2019, http://dx.doi.org/10.1200/JCO.2019.37.7_suppl.TPS332

Liu W; Chung HT; Chung P; Zukotynski K; Metser U; Rachinsky I; Wolfson R; Archer S; Emmett L; Bauman GS, 2018, 'Advanced Prostate Imaging of Recurrent Cancer after Radiation Therapy (PICs): Interim Results of a Prospective, Multi-Center Trial', in INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, ELSEVIER SCIENCE INC, TX, San Antonio, Vol. 102, pp. E126 - E126, presented at 60th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO), TX, San Antonio, 21 October 2018 - 24 October 2018, http://dx.doi.org/10.1016/j.ijrobp.2018.07.337

Gielchinsky I; Chang J; Emmett L; Scheltema M; Stricker P; Nguyen Q; Delprado W, 2018, 'False positive intraprostatic lesions on 68 Ga Positron emission tomography in an intermediate prostate cancer cohort: description of a benign cystic cellular pattern with intense PSMA activity', in BJU INTERNATIONAL, WILEY, AUSTRALIA, Melbourne, Vol. 121, pp. 74 - 75, presented at 71st Annual Scientific Meeting of the Urological-Society-of-Australia-and-New-Zealand, AUSTRALIA, Melbourne, 24 February 2018 - 27 February 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000425625700159&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Roach P; Francis R; Emmett L; McCarthy M; Scott A, 2017, 'Clinical management intent of Ga68 PSMA PET/CT imaging in prostate cancer: an Australian multicentre study', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, CO, Denver, Vol. 58, presented at Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI), CO, Denver, 10 June 2017 - 14 June 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000404949903106&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Siriwardana A; Thompson J; Doig S; Kalsbeek A; Emmett L; Delprado W; Wong D; Samaratunga H; Haynes A-M; Coughlin G; Stricker P, 2017, 'Robot-assisted salvage node dissection for oligometastatic nodal disease detected by 68gallium-PSMA PET/CT: a multicentre retrospective series', in BJU INTERNATIONAL, WILEY-BLACKWELL, Canberra, AUSTRALIA, Vol. 119, pp. 78 - 79, presented at 70th Annual Scientific Meeting of the Urological-Society-of-Australia-and-New-Zealand, Canberra, AUSTRALIA, 24 February 2017 - 27 February 2017, http://dx.doi.org/10.1016/j.juro.2017.02.1661

Back to profile page